Form 4: Jazz Pharmaceuticals Executive Acquires Shares and Restricted Stock Units

Samantha Pearce, EVP and Chief Commercial Officer of Jazz Pharmaceuticals, reports acquisition of shares and restricted stock units.

Summary

• On August 2, 2024, Samantha Pearce, EVP, Chief Commercial Officer of Jazz Pharmaceuticals, acquired 6,996 ordinary shares.
• These shares were granted as restricted stock units under the company's 2011 Equity Incentive Plan.
• The restricted stock units vest in equal annual installments over four years, starting August 5, 2024.
• Pearce also owns 160 ordinary shares acquired on May 31, 2024, under a Section 423 Employee Stock Purchase Plan.
• Following the reported transaction, Pearce beneficially owns 24,078 ordinary shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard executive compensation practices and insider confidence through stock ownership.

Positives

• The grant of restricted stock units aligns the executive's interests with those of the shareholders.
• Participation in the employee stock purchase plan demonstrates confidence in the company's future.

Industry Context

Executive compensation through stock options and restricted stock units is a common practice in the pharmaceutical industry to incentivize performance and align executive interests with shareholder value.

Stakeholder Impact

• Shareholders may view the grant of restricted stock units as a positive sign, aligning executive interests with company performance.
• Employees may be motivated by the availability of an Employee Stock Purchase Plan.

Key Dates